Background

Systemic inflammatory response in diffuse large B-cell lymphoma (DLBCL) is closely related to disease prognosis. Our aim is to determine the role of pretreatment platelet-to-lymphocyte ratio (PLR) in predicting early treatment response in DLBCL patients.

Methods

This retrospective study included 94 patients. The correlation of PLR at the time of diagnosis with early treatment response was evaluated.

Results

66 patients responded to treatment and 28 patients were unresponsive or partially responsive. In univariate analysis, age, eastern cooperative oncology group performance status (ECOG-PS), disease stage, extranodal involvement, neutrophil-to-lymphocyte ratio (NLR), PLR, hemoglobin, albumin, lymphocyte, platelet (HALP) score were found to predict response to treatment. Multivariate analysis revealed that PLR and ECOG-PS were independent predictors of early treatment response.

Conclusion

PLR can be used by clinicians as an effective, inexpensive inflammatory parameter supplementary to the IPI score to predict early treatment response to chemoimmunotherapy. Treatment of patients with DLBCL with high PLR at the time of diagnosis with more potent regimens may be a rational approach for patients to benefit more from treatment.

中文翻译：

---

血小板与淋巴细胞比 (PLR) 在预测弥漫性大 B 细胞淋巴瘤早期治疗反应中的作用

 背景

弥漫性大B细胞淋巴瘤（DLBCL）的全身炎症反应与疾病预后密切相关。我们的目的是确定治疗前血小板与淋巴细胞比率 (PLR) 在预测 DLBCL 患者早期治疗反应中的作用。

 方法

这项回顾性研究包括 94 名患者。评估诊断时的 PLR 与早期治疗反应的相关性。

 结果

66 名患者对治疗有反应，28 名患者无反应或部分反应。在单变量分析中，发现年龄、东部肿瘤协作组表现状态（ECOG-PS）、疾病分期、结外受累、中性粒细胞与淋巴细胞比率（NLR）、PLR、血红蛋白、白蛋白、淋巴细胞、血小板（HALP）评分与预测对治疗的反应。多变量分析显示 PLR 和 ECOG-PS 是早期治疗反应的独立预测因子。

 结论

临床医生可以将 PLR 用作 IPI 评分的有效、廉价的炎症参数补充，以预测对化学免疫疗法的早期治疗反应。对于诊断时具有高 PLR 的 DLBCL 患者，采用更有效的治疗方案进行治疗可能是一种合理的方法，可以让患者从治疗中获得更多益处。